Menu Search
Equities

iZafe Group AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
M02:STU

iZafe Group AB

Actions
  • Price (EUR)0.001
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-90.20%
  • Beta-0.1430
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

iZafe Group AB is a Sweden-based medical technology company that develops and markets medical and digital safety solutions to create safer medication management at home. The Company's focus is on providing products and services that enhance medication safety and improve the overall well-being of individuals. It is engaged in the development of digital drug dispensing through the pharmaceutical robot Dosell as well as The Software as a service (SaaS) solution with the connected dose bag Pillbox. The company's solutions reduce the risk of incorrect medication in the home, public care, increases the quality of life for patients and creates a safer environment for relatives. The customers are private individuals, pharmaceutical companies and public and private healthcare providers.

  • Revenue in SEK (TTM)5.90m
  • Net income in SEK-17.73m
  • Incorporated2008
  • Employees10.00
  • Location
    iZafe Group ABDavid bagares gata 3STOCKHOLM 111 38SwedenSWE
  • Phone+46 8211121
  • Fax+46 87656633
  • Websitehttps://izafe.se/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IZAFE B:STO since
announced		Transaction
value
Thuisapparatuur Nederland BVAnnounced30 Sep 202530 Sep 2025Announced-1.33%1.82m
Data delayed at least 15 minutes, as of Feb 06 2026 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.